Par Drugs Q1 FY27 Results: Revenue Rs 31 Cr, PAT Rs 4.00 Cr and Key Highlights
- August 10, 2026
- Posted by: Kunal Singla
- Category: News
Par Drugs Q1 FY27 results declared August 8, 2026. Revenue Rs 31 Cr (+20.10% YoY). PAT Rs 4.00 Cr (+41.60% YoY). CMP Rs 98.4 (-2.5%).
Par Drugs Q1 FY27 results were announced on August 8, 2026, standalone. Revenue grew +20.10% YoY to Rs 31 Cr from Rs 26 Cr in Q1 FY26. The broader Nifty Pharma index reflected mixed sentiment during the quarter.
Operating profit stood at Rs 5.00 Cr (+103.82% YoY). PAT came in at Rs 4.00 Cr (+41.60% YoY), offering a comprehensive view of how Par Drugs is navigating the current pharmaceuticals environment.
Click Here – Get Free Investment Predictions
Par Drugs Q1 FY27 Financial Highlights
| Metric | Q1 FY27 (Rs Cr) | Q1 FY26 (Rs Cr) | YoY Change |
|---|---|---|---|
| Par Drugs Revenue | 31 | 26 | +20.10% |
| Operating Profit | 5.00 | 2.00 | +103.82% |
| Net Profit (PAT) | 4.00 | 3.00 | +41.60% |
| Reporting Basis | Standalone | ||
Par Drugs Q1 FY27 Performance Analysis
Check the Univest Screener for Live Data on This Stock
Par Drugs Q1 FY27 results reflect healthy fundamentals across key financial metrics. Revenue momentum stayed robust with the top line reaching Rs 31 Cr for the April to June 2026 quarter.
Operating profit expanded +103.82% YoY to Rs 5.00 Cr. This indicates improving cost efficiency and better product mix.
PAT of Rs 4.00 Cr marks a +41.60% YoY movement in Par Drugs Q1 FY27 results. Investors monitoring Par Drugs Q1 FY27 results will note this as a key FY27 performance milestone.
Key Business Factors in Par Drugs Q1 FY27 Results
Revenue Expansion Driving Top-Line Growth
Par Drugs Q1 FY27 results show top-line strength with revenue growing +20.10% YoY to Rs 31 Cr from Rs 26 Cr in Q1 FY26. Order execution momentum and market share gains in the Pharmaceuticals segment fuelled this expansion.
Operating Leverage and Margin Improvement
Operating profit in Par Drugs Q1 FY27 results improved +103.82% YoY to Rs 5.00 Cr, reflecting better cost control, improving product mix, and operating leverage as the company scales volumes.
PAT Performance and Profitability Trend
Net profit (PAT) in Par Drugs Q1 FY27 results stood at Rs 4.00 Cr ((+41.60% YoY)). Improving PAT trajectory signals strengthening financial health.
Dividend Details
No dividend was announced alongside Par Drugs Q1 FY27 results. The company is likely channelling earnings toward business reinvestment and working capital needs.
FY27 Outlook for Par Drugs
Par Drugs is well-positioned to sustain growth momentum through FY27, backed by order visibility, sector tailwinds, and operational improvements. Management guidance points to continued expansion in the pharmaceuticals segment with a focus on margin improvement. Investors tracking Par Drugs Q1 FY27 results should consult a SEBI-registered financial advisor before making investment decisions.
Par Drugs Stock Performance After Q1 FY27 Results
Download the Univest iOS App or Univest Android App to track Par Drugs live price and get daily stock recommendations.
Par Drugs shares were trading lower at Rs 98.4 (-2.5%) on August 8, 2026, reflecting investor sentiment on the Par Drugs Q1 FY27 results and near-term sector outlook. The CMP of Rs 98.4 on the results date reflects broader market and sector sentiment in the pharmaceuticals space.
Key Risks for Par Drugs
Sector-Specific Risks
USFDA regulatory actions, pricing pressure, and API cost inflation are core risks.
Valuation and Earnings Risk
Valuation risk if quarterly growth momentum fails to sustain over the next two to three quarters.
Operational and Financial Risk
Working capital intensity and cash conversion cycle elongation could strain standalone cash flows.
Conclusion
Par Drugs Q1 FY27 results reflect healthy performance with revenue at Rs 31 Cr and PAT at Rs 4.00 Cr on a Standalone basis. Operating leverage and sector tailwinds will determine the FY27 growth trajectory. Investors should review management commentary and sector developments before taking positions.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Par Drugs Q1 FY27 Results
When were Par Drugs Q1 FY27 results declared?
Ans. Par Drugs Q1 FY27 results were declared on August 8, 2026, covering the April to June 2026 quarter on a Standalone basis.
What was Par Drugs revenue in Q1 FY27?
Ans. Par Drugs Q1 FY27 results show revenue of Rs 31 Cr, +20.10% compared to Rs 26 Cr in Q1 FY26.
What was Par Drugs PAT in Q1 FY27?
Ans. Net profit in Par Drugs Q1 FY27 results was Rs 4.00 Cr, +41.60% year-on-year.
Did Par Drugs declare a dividend in Q1 FY27?
Ans. No dividend was announced alongside Par Drugs Q1 FY27 results. Check the official NSE and BSE announcements for future dividend declarations.
What is the FY27 outlook for Par Drugs?
Ans. Management has guided revenue growth and margin improvement for FY27. Sector trends and order visibility will be key monitorables for investors.
How did Par Drugs stock react to Q1 FY27 results?
Ans. Par Drugs shares were trading lower at Rs 98.4 (-2.5%) on August 8, 2026 following the Par Drugs Q1 FY27 results. Always consult a SEBI-registered financial advisor before acting on stock price movements.
